EW bullish thesis: growth in transcatheter heart valves and structural heart market

What happened: Edwards Lifesciences (EW), a leading medtech company, raised its full-year 2026 growth outlook to 9-11% following a strong Q1 performance. The company reported revenues of $1.65bn, driven by steady double-digit growth across its portfolio, particularly in transcatheter heart valves and structural heart products.

Market impact: This bullish development signals robust demand and growth potential in the transcatheter heart valves and structural heart market. Competitors like Medtronic (MDT) and Abbott (ABT) may face increased pressure to match EW's growth, potentially driving further innovation and investment in the sector.

What to watch next: EW's next quarterly earnings report (expected in late April) will provide further insight into the company's growth trajectory. Additionally, regulatory decisions on EW's pipeline products, such as the PASCAL Transcatheter Valve Repair System, could significantly impact the company's growth prospects and the broader market.